City

Beijing (1)

Calgary (1)

San Diego (1)

Taipei (1)

Taipei City (1)

Overall Status

Recruiting (3)

Completed (2)

Phase

phase 2 (1)

phase 4 (1)

Sponsor

German Cancer Research Center (1)

Lei Li (1)

National Taiwan University Hospital (1)

University of Calgary (1)

University of California, San Diego (1)

Collaborator

Dr. Sandra Dumanski (1)

Intervention

abemaciclib (1)

angiotensin ii (1)

emtricitabine / tenofovir disoproxil oral tablet 200/300 mg (1)

emtricitabine tenofovir alafenamide 200/25 mg (1)

letrozole (1)

palbociclib (1)

ribociclib (1)

surgical treatment with and without fertility-sparing procedures (1)

Study Documents

Intervention Type

drug (3)

procedure (1)

Funder Type

Other (5)

Study Type

Observational (3)

Interventional (2)

hormone therapy

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy Trial in Taipei City, Taipei (Palbociclib, Ribociclib,

Recruiting

Breast Cancer
+2 more

Palbociclib
+3 more

Taipei City, Taiwan
+1 more

Mar 15, 2023

Hiv, Hormone Therapy Trial in San Diego (Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg, Emtricitabine Tenofovir

Completed

Hiv
Hormone Therapy

Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg
Emtricitabine Tenofovir Alafenamide 200/25 mg

San Diego, California

UC San Diego AntiViral Research Center (AVRC)

Sep 21, 2022

Angiotensin-Dependent Arterial and Renal Vasoconstriction in

Recruiting

Hormone Therapy

Angiotensin II

Calgary, Alberta, Canada

University of Calgary

Jun 28, 2022

Prognosis of Low-grade Endometrial Stromal Sarcoma

Recruiting

Low Grade Endometrial Stromal Sarcoma of Uterus (Diagnosis)
+6 more

Surgical treatment with and without fertility-sparing procedures

Beijing, Beijing, China

Lei Li

Mar 26, 2022

Genetic Factors on Long-term Breast Cancer Prognosis

Completed

Breast Cancer
+9 more

(no location specified)

Jan 15, 2018